Filing Details

Accession Number:
0001209191-21-009132
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-09 21:30:30
Reporting Period:
2021-02-08
Accepted Time:
2021-02-09 21:30:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724097 Matt Abernethy 12780 El Camino Real
San Diego CA 92130
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-08 880 $116.85 13,043 No 4 S Direct
Common Stock Disposition 2021-02-08 2,030 $116.81 14,869 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Acquisiton 2021-02-08 44,632 $0.00 44,632 $117.63
Common Stock Restricted Stock Unit Acquisiton 2021-02-08 7,439 $0.00 7,439 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
44,632 2031-02-08 No 4 A Direct
7,439 No 4 A Direct
Footnotes
  1. Sale of 880 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,549) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.9394 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
  6. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
  7. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.